Nasal polyps as possible target to achieve the best biological treatment choice in severe asthma

Le résumé fourni par la source

Nasal polyposis (NS) is one of the most impacting comorbidity on severe asthma (SA) control. A biological targeted therapy for SA might consider NP response. We evaluated in a large cohort of SA patients the main features related to NP severity aiming to achieve the best therapeutic choice. We enrolled 100 patients with SA. We recorded clinical and demographic data, particularly atopic features (skin prick test positivity, specific serum IgE, aspirin intolerance). Patients received a complete upper and lower airway evaluation, including nasal endoscopy, induced sputum and cytological analysis of nasal smear. NP was graded according to the HOX endoscopy score. Sino-Nasal Outcome Test (SNOT), ACT Score and the Short Form (SF)-36 were used. Sputum eosinophils were significantly related to NP, while atopic features were not. Sputum and blood eosinophils were related. ACT was related to blood eosinophilia and FEV1. Eosinophilia in nasal smear was significantly related to NP and HOX endoscopy score. SNOT was related to SF36 questionnaire. In conclusion, NP has a major impact on nasal and sputum eosinophilia, while it is not related to atopic features. These findings might help achieve the best biological treatment choice for SA patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.